Want to see SE:ERMA full AI Analyst Report?
ERMA Stock Chart & Stats
kr1.91
-kr0.30(-12.50%)
At close: 4:00 PM EST
kr1.91
-kr0.30(-12.50%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr3.58
Previous CloseN/A
Volume29.79K
Average Volume (3M)4.35K
Market Cap
kr22.08M
Enterprise Valuekr8.12M
Total Cash (Recent Filing)kr17.76M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding74,588,684
10 Day Avg. Volume2,975
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.66
Price to Sales (P/S)48.45
P/FCF Ratio-2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing / Partnering ModelEnorama’s asset-light model focuses on developing patented nicotine replacement formulations and monetizing through partners via upfronts, milestones and royalties. This reduces capital intensity and distribution risk, allowing scale through partner execution rather than building a costly sales infrastructure.
Very Low Financial LeverageNear-zero debt materially lowers insolvency and interest-service risk, preserving flexibility to pursue licensing deals or R&D. With limited leverage the company can negotiate partnerships from a less constrained capital-structure position, although funding for operations remains a separate challenge.
Has Demonstrated Positive Gross ProfitRecording positive gross profit in 2024 indicates the firm’s formulations can produce viable unit economics when scaled or paired with efficient manufacturing/partners. This historical profitability at the gross level supports the structural potential for margin recovery with successful commercialization or partner-led scale.
Bears Say
Shrinking Revenue BaseA small and shrinking revenue base undermines the company’s ability to prove commercial traction to partners, absorb fixed R&D overheads, and build sustainable operating scale. Persistently falling top-line reduces bargaining power in licensing talks and lengthens the path to self-sustaining operations.
Persistent Operating Cash BurnMulti-year negative operating and free cash flow require recurrent external financing or dilutive capital raises, constraining long-term investment and making sustained product development dependent on third-party funding. Chronic cash burn elevates execution risk for clinical/development milestones.
Negative Shareholders' EquityNegative equity signals accumulated losses and weak capital base, limiting financial flexibility and increasing reliance on new capital or restructuring. It can impede partner confidence, trigger covenant or listing risks, and raises the probability of dilutive financings that affect long-term shareholder value.
ERMA FAQ
What was Enorama Pharma AB’s price range in the past 12 months?
Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.58 in the past 12 months.
What is Enorama Pharma AB’s market cap?
Enorama Pharma AB’s market cap is kr22.08M.
When is Enorama Pharma AB’s upcoming earnings report date?
Enorama Pharma AB’s upcoming earnings report date is Aug 19, 2026 which is in 44 days.
How were Enorama Pharma AB’s earnings last quarter?
Enorama Pharma AB released its earnings results on May 20, 2026. The company reported -kr0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.17.
Is Enorama Pharma AB overvalued?
According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued.
Does Enorama Pharma AB pay dividends?
Enorama Pharma AB does not currently pay dividends.
What is Enorama Pharma AB’s EPS estimate?
Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enorama Pharma AB have?
Enorama Pharma AB has 74,588,684 shares outstanding.
What happened to Enorama Pharma AB’s price movement after its last earnings report?
Enorama Pharma AB reported an EPS of -kr0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 23.333%.
Which hedge fund is a major shareholder of Enorama Pharma AB?
Currently, no hedge funds are holding shares in SE:ERMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.